Your browser doesn't support javascript.
loading
Alzheimer's Disease in Systemic Sclerosis Patients: A Nationwide Population-Based Cohort Study.
Watad, Abdulla; Bragazzi, Nicola L; Tiosano, Shmuel; Yavne, Yarden; Comaneshter, Doron; Cohen, Arnon D; Amital, Howard.
Afiliação
  • Watad A; Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel.
  • Bragazzi NL; The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
  • Tiosano S; Sackler Faculty of Medicine, Tel-Aviv University, Israel.
  • Yavne Y; Department of Health Sciences (DISSAL), School of Public Health, University of Genoa, Genoa, Italy.
  • Comaneshter D; Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel.
  • Cohen AD; Sackler Faculty of Medicine, Tel-Aviv University, Israel.
  • Amital H; Department of Medicine 'B', Sheba Medical Center, Tel-Hashomer, Israel.
J Alzheimers Dis ; 65(1): 117-124, 2018.
Article em En | MEDLINE | ID: mdl-30040736
ABSTRACT

BACKGROUND:

Neurological features are often overlooked in systemic sclerosis (SSc) patients and little is known about the link between dementia and SSc.

OBJECTIVES:

We sought to investigate whether an association exists between Alzheimer's disease (AD) and SSc, as well as assess the impact of a dual diagnosis on mortality rates, by performing an extensive data analysis on a large subject sample.

METHODS:

We utilized the medical database of the Clalit-Health-Services in a case-control study. Patients with SSc were compared with age- and sex-matched controls with regard to the prevalence of AD and its impact on their mortality.

RESULTS:

Our study included 2,431 SSc patients and 12,377 age- and sex-matched controls. The mean age of the study population was 63.32±18.06 years and the female to male ratio was 4.51. 134 (5.5%) cases had AD as a co-morbidity in comparison with 749 (5.9%) of the controls. The mortality rate was 12.5% among controls and 26.2% among SSc cases. On the Cox multivariate survival analysis, diagnosis of SSc and AD demonstrated significant HRs (2.35 (95% CI 2.05-2.69, p < 0.0001) and 2.19 (95% CI 1.94-2.48, p < 0.0001), respectively). SSc patients with AD had a relative risk of death of 2.35 (95% CI 1.44-3.83) in comparison with SSc patients without AD.

CONCLUSION:

AD is a predictor of death in SSc and therefore preemptive screening may be warranted. Further studies are needed to evaluate whether improvements in the medical regimen for SSc may lead to a reduction in AD development and possibly to increased survival as well.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Doença de Alzheimer Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Alzheimers Dis Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Escleroderma Sistêmico / Doença de Alzheimer Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Alzheimers Dis Ano de publicação: 2018 Tipo de documento: Article